Cargando…

IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model

The protocol used to induce cell death for generating vaccines from whole tumor cells is a critical consideration that impacts vaccine efficacy. Here we compared how different protocols used to induce cell death impacted protection provided by a prophylactic whole tumor cell vaccine in a mouse melan...

Descripción completa

Detalles Bibliográficos
Autores principales: Seaver, Kyle, Kourko, Olena, Gee, Katrina, Greer, Peter A., Basta, Sameh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069009/
https://www.ncbi.nlm.nih.gov/pubmed/35529885
http://dx.doi.org/10.3389/fimmu.2022.884827
_version_ 1784700344334286848
author Seaver, Kyle
Kourko, Olena
Gee, Katrina
Greer, Peter A.
Basta, Sameh
author_facet Seaver, Kyle
Kourko, Olena
Gee, Katrina
Greer, Peter A.
Basta, Sameh
author_sort Seaver, Kyle
collection PubMed
description The protocol used to induce cell death for generating vaccines from whole tumor cells is a critical consideration that impacts vaccine efficacy. Here we compared how different protocols used to induce cell death impacted protection provided by a prophylactic whole tumor cell vaccine in a mouse melanoma model. We found that melanoma cells exposed to γ-irradiation or lysis combined with UV-irradiation (LyUV) provided better protection against tumor challenge than lysis only or cells exposed to UV-irradiation. Furthermore, we found that the immunoregulatory cytokine, IL-27 enhanced protection against tumor growth in a dose-dependent manner when combined with either LyUV or γ-irradiated whole tumor cell vaccine preparations. Taken together, this data supports the use of LyUV as a potential protocol for developing whole tumor cell prophylactic cancer vaccines. We also showed that IL-27 can be used at low doses as a potent adjuvant in combination with LyUV or γ-irradiation treated cancer cells to improve the protection provided by a prophylactic cancer vaccine in a mouse melanoma model.
format Online
Article
Text
id pubmed-9069009
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90690092022-05-05 IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model Seaver, Kyle Kourko, Olena Gee, Katrina Greer, Peter A. Basta, Sameh Front Immunol Immunology The protocol used to induce cell death for generating vaccines from whole tumor cells is a critical consideration that impacts vaccine efficacy. Here we compared how different protocols used to induce cell death impacted protection provided by a prophylactic whole tumor cell vaccine in a mouse melanoma model. We found that melanoma cells exposed to γ-irradiation or lysis combined with UV-irradiation (LyUV) provided better protection against tumor challenge than lysis only or cells exposed to UV-irradiation. Furthermore, we found that the immunoregulatory cytokine, IL-27 enhanced protection against tumor growth in a dose-dependent manner when combined with either LyUV or γ-irradiated whole tumor cell vaccine preparations. Taken together, this data supports the use of LyUV as a potential protocol for developing whole tumor cell prophylactic cancer vaccines. We also showed that IL-27 can be used at low doses as a potent adjuvant in combination with LyUV or γ-irradiation treated cancer cells to improve the protection provided by a prophylactic cancer vaccine in a mouse melanoma model. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9069009/ /pubmed/35529885 http://dx.doi.org/10.3389/fimmu.2022.884827 Text en Copyright © 2022 Seaver, Kourko, Gee, Greer and Basta https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Seaver, Kyle
Kourko, Olena
Gee, Katrina
Greer, Peter A.
Basta, Sameh
IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model
title IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model
title_full IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model
title_fullStr IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model
title_full_unstemmed IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model
title_short IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model
title_sort il-27 improves prophylactic protection provided by a dead tumor cell vaccine in a mouse melanoma model
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069009/
https://www.ncbi.nlm.nih.gov/pubmed/35529885
http://dx.doi.org/10.3389/fimmu.2022.884827
work_keys_str_mv AT seaverkyle il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel
AT kourkoolena il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel
AT geekatrina il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel
AT greerpetera il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel
AT bastasameh il27improvesprophylacticprotectionprovidedbyadeadtumorcellvaccineinamousemelanomamodel